Skip to main content
Delfa

← All assets

ACI-24.060

1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

1

Ongoing

1

Recruiting

1

Completed

0

Sites

26

Countries

3

Endpoints

19

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 19 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1/2
1

Trials by status

Recruiting
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
4
Amyloid biomarkers
4
Neuroimaging
3
Memory
2
Behavior / neuropsychiatric
2
Safety / tolerability / PK
2
Other (unclassified)
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 1 of 19 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

1 of 1

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT05462106A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

ACI-24.060

Alzheimer’s disease

MCI due to AD / prodromal ADPh 1/2Recruiting26Apr 2029-

Showing 1-1 of 1 trials